BR112017003705B1 - Compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea - Google Patents

Compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea Download PDF

Info

Publication number
BR112017003705B1
BR112017003705B1 BR112017003705-0A BR112017003705A BR112017003705B1 BR 112017003705 B1 BR112017003705 B1 BR 112017003705B1 BR 112017003705 A BR112017003705 A BR 112017003705A BR 112017003705 B1 BR112017003705 B1 BR 112017003705B1
Authority
BR
Brazil
Prior art keywords
dihydro
mmol
methyl
piperidinyl
amino
Prior art date
Application number
BR112017003705-0A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112017003705A2 (pt
Inventor
Katherine Louisa Widdowson
Original Assignee
Glaxosmithkline Intellectual Property Development Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property Development Limited filed Critical Glaxosmithkline Intellectual Property Development Limited
Publication of BR112017003705A2 publication Critical patent/BR112017003705A2/pt
Publication of BR112017003705B1 publication Critical patent/BR112017003705B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112017003705-0A 2014-08-22 2015-08-20 Compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea BR112017003705B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462040488P 2014-08-22 2014-08-22
US62/040,488 2014-08-22
PCT/IB2015/056325 WO2016027249A1 (en) 2014-08-22 2015-08-20 Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection

Publications (2)

Publication Number Publication Date
BR112017003705A2 BR112017003705A2 (pt) 2017-12-05
BR112017003705B1 true BR112017003705B1 (pt) 2022-07-12

Family

ID=54072911

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017003705-0A BR112017003705B1 (pt) 2014-08-22 2015-08-20 Compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea

Country Status (22)

Country Link
US (2) US10702521B2 (enExample)
EP (2) EP3639824A1 (enExample)
JP (2) JP6546654B2 (enExample)
KR (1) KR20170043603A (enExample)
CN (2) CN110403939A (enExample)
AR (1) AR101674A1 (enExample)
AU (1) AU2015304847B2 (enExample)
BR (1) BR112017003705B1 (enExample)
CA (1) CA2958800C (enExample)
CL (1) CL2017000391A1 (enExample)
CO (1) CO2017001658A2 (enExample)
CR (1) CR20170069A (enExample)
DO (1) DOP2017000049A (enExample)
EA (1) EA031589B1 (enExample)
ES (1) ES2759303T3 (enExample)
IL (1) IL250251A0 (enExample)
MX (1) MX2017002321A (enExample)
PE (1) PE20170501A1 (enExample)
PH (1) PH12017500315A1 (enExample)
SG (1) SG11201700566SA (enExample)
TW (1) TW201618779A (enExample)
WO (1) WO2016027249A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR101674A1 (es) * 2014-08-22 2017-01-04 Glaxosmithkline Ip Dev Ltd Uso de un compuesto tricíclico que contiene nitrógeno
PL3468975T3 (pl) 2016-06-08 2020-09-07 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Nowe związki przeciwbakteryjne
AU2017374992A1 (en) 2016-12-16 2019-06-20 Basf Se Pesticidal compounds
JP2022528890A (ja) * 2019-04-03 2022-06-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 細菌性尿路感染症の治療に使用するためのゲポチダシン
US20220184071A1 (en) * 2019-04-03 2022-06-16 Glaxosmithkline Intellectual Property Development Limited Gepotidacin for use in the treatment of bacterial urinary tract infections
GB201909191D0 (en) * 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
CA3143619A1 (en) * 2019-07-05 2021-01-14 Glaxosmithkline Intellectual Property Development Limited Combination for the treatment of infections caused by mycoplasma genitalium
JP7765088B2 (ja) 2019-12-02 2025-11-06 ストーム・セラピューティクス・リミテッド Ｍｅｔｔｌ３阻害剤としてのポリヘテロ環式化合物
BR112022018315A2 (pt) 2020-04-02 2022-10-25 Glaxosmithkline Ip Dev Ltd Regime para tratar a infecção por neisseria gonorrhoeae com gepotidacina
EP4142731A1 (en) * 2020-04-28 2023-03-08 Noorik Biopharmaceuticals AG Treatment of pulmonary complications of coronavirus infections
CN115667261A (zh) * 2020-04-29 2023-01-31 葛兰素史克知识产权发展有限公司 吉泊达星的结晶形式
EP4288035A1 (en) 2021-02-05 2023-12-13 GlaxoSmithKline Intellectual Property Development Limited Oral solid dose formulations
EP4316463A1 (en) 2022-08-02 2024-02-07 GlaxoSmithKline Intellectual Property Development Limited Novel formulation
JP2025532252A (ja) 2022-09-26 2025-09-29 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 処置方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2090767A1 (en) 1992-03-06 1993-09-07 Gerald Guillaumet 1,4-dioxino[2,3-b]pyridine derivatives
ES2145072T3 (es) * 1993-05-13 2000-07-01 American Cyanamid Co Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos.
GB0207450D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
FR2798656B1 (fr) 1999-09-17 2004-12-17 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent
EP1306038B1 (en) 2000-07-21 2005-12-21 Ljudmila Petrovna Maljuk Plate for a stand-up meal
JP2004504397A (ja) 2000-07-26 2004-02-12 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー 抗菌活性を有するアミノピペリジンキノリン類およびそれらのアザイソステリックアナログ類
AR037080A1 (es) 2000-09-29 2004-10-20 Glaxo Group Ltd Compuestos utiles en el tratamiento de enfermedades inflamatorias,composiciones que los contienen, su uso en terapia, metodos de tratamiento, procesos de preparacion e intermediarios
FR2816618B1 (fr) 2000-11-15 2002-12-27 Aventis Pharma Sa Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
US20040063961A1 (en) 2000-12-21 2004-04-01 Van Der Schaaf Paul Adriaan Crystalline forms of cerivastatin sodium
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
AU2002350217A1 (en) 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
WO2003064431A2 (en) 2002-01-29 2003-08-07 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
JP4445753B2 (ja) 2002-01-29 2010-04-07 グラクソ グループ リミテッド アミノピペリジン誘導体
AR040336A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
TW200406413A (en) 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
GB0217294D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
FR2844268B1 (fr) 2002-09-11 2004-10-22 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent
FR2844270B1 (fr) 2002-09-11 2006-05-19 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent
US7223776B2 (en) 2002-10-10 2007-05-29 Morphochem Ag Compounds with anti-bacterial activity
ES2340484T3 (es) 2002-11-05 2010-06-04 Glaxo Group Limited Agentes antibacterianos.
EP1560488B1 (en) 2002-11-05 2010-09-01 Glaxo Group Limited Antibacterial agents
AR042486A1 (es) 2002-12-18 2005-06-22 Glaxo Group Ltd Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
TW200507841A (en) 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
FR2852954B1 (fr) 2003-03-28 2006-07-14 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
DE10316081A1 (de) 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
WO2004104000A1 (ja) 2003-05-23 2004-12-02 Japan Tobacco Inc. トリサイクリック縮合環化合物およびその医薬用途
FR2858619B1 (fr) 2003-08-08 2006-12-22 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
FR2867472B1 (fr) 2004-03-12 2008-07-18 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
US7691850B2 (en) 2004-06-15 2010-04-06 Glaxo Group Limited Antibacterial agents
FR2872164B1 (fr) 2004-06-29 2006-11-17 Aventis Pharma Sa Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
JP2008505920A (ja) 2004-07-08 2008-02-28 グラクソ　グループ　リミテッド 抗菌剤
EP1773847A2 (en) 2004-07-09 2007-04-18 Glaxo Group Limited Antibacterial agents
JP2008506695A (ja) 2004-07-13 2008-03-06 グラクソ　グループ　リミテッド 抗細菌剤
EP1778688A1 (en) 2004-07-22 2007-05-02 Glaxo Group Limited Antibacterial agents
ATE484509T1 (de) 2004-08-02 2010-10-15 Glaxo Group Ltd Antibakterielle mittel
EP1784410A4 (en) 2004-08-09 2009-07-15 Glaxo Group Ltd ANTIBACTERIAL AGENTS
DE102004041163A1 (de) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
CA2580621A1 (en) 2004-09-24 2006-03-30 Actelion Pharmaceuticals Ltd New bicyclic antibiotics
ES2343127T3 (es) 2004-10-05 2010-07-23 Actelion Pharmaceuticals Ltd. Nuevos antibioticos de piperidina.
WO2006046552A1 (ja) 2004-10-27 2006-05-04 Toyama Chemical Co., Ltd. 新規な含窒素複素環化合物およびその塩
WO2006081179A1 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
WO2006081289A2 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
JP2008528586A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
US7592334B2 (en) 2005-01-25 2009-09-22 Glaxo Group Limited Antibacterial agents
WO2006081264A1 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
WO2006099884A1 (en) 2005-03-24 2006-09-28 Actelion Percurex Ag Beta-aminoalcohol antibiotics
EP1863483A4 (en) 2005-03-31 2010-03-31 Janssen Pharmaceutica Nv Bicyclic pyrazole compounds as anti-bacteriostatic agents
AR053602A1 (es) 2005-05-03 2007-05-09 Smithkline Beecham Corp Compuesto de 2- arilamino -4-oxo-1,3-tiazol-5(4h)- substituido, composicion farmaceutica que lo comprende, proceso para prepararla y uso del compuesto para preparar un medicamento
AU2006250987A1 (en) 2005-05-24 2006-11-30 Astrazeneca Ab Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
ES2330670T3 (es) 2005-05-25 2009-12-14 Actelion Pharmaceuticals Ltd. Nuevos derivados antibioticos.
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
EP2468743A1 (en) 2005-06-24 2012-06-27 Toyama Chemical Co., Ltd. Nitrogen-containing bicyclic compounds useful as antibacterial agents
WO2007016610A2 (en) 2005-08-02 2007-02-08 Glaxo Group Limited Antibacterial agents
DE602006012535D1 (de) 2005-10-21 2010-04-08 Glaxo Group Ltd Peri-kondensierte tricyclische verbindungen verwendbar als antibakterielle mittel
CA2630517A1 (en) 2005-12-06 2007-06-14 Merck & Co., Inc. Morpholine carboxamide prokineticin receptor antagonists
US20070185153A1 (en) 2005-12-22 2007-08-09 Nathalie Cailleau Compounds
DE602007009205D1 (de) 2006-04-06 2010-10-28 Glaxo Group Ltd Pyrrolochinoxalinonderivate als antibakterielle mittel
EP2007377A4 (en) 2006-04-06 2011-08-17 Glaxo Group Ltd ANTIBACTERIAL ACTIVE SUBSTANCES
GB0608263D0 (en) 2006-04-26 2006-06-07 Glaxo Group Ltd Compounds
US20100256124A1 (en) 2006-06-09 2010-10-07 David Thomas Davies Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials
GB0613208D0 (en) 2006-07-03 2006-08-09 Glaxo Group Ltd Compounds
EP1992628A1 (en) 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
WO2008128942A1 (en) * 2007-04-20 2008-10-30 Glaxo Group Limited Tricyclic nitrogen containing compounds as antibacterial agents
CN102105473B (zh) * 2008-05-23 2013-05-08 葛兰素集团有限公司 三环含氮化合物及其作为抗菌剂的用途
JP2012505866A (ja) 2008-10-17 2012-03-08 グラクソ グループ リミテッド 抗菌剤として使用される三環式窒素化合物
AR101674A1 (es) * 2014-08-22 2017-01-04 Glaxosmithkline Ip Dev Ltd Uso de un compuesto tricíclico que contiene nitrógeno

Also Published As

Publication number Publication date
EP3182973A1 (en) 2017-06-28
JP2017524029A (ja) 2017-08-24
US11229646B2 (en) 2022-01-25
MX2017002321A (es) 2017-08-02
DOP2017000049A (es) 2017-03-15
CA2958800A1 (en) 2016-02-25
KR20170043603A (ko) 2017-04-21
WO2016027249A1 (en) 2016-02-25
PE20170501A1 (es) 2017-04-27
US10702521B2 (en) 2020-07-07
CO2017001658A2 (es) 2017-07-19
SG11201700566SA (en) 2017-03-30
ES2759303T3 (es) 2020-05-08
PH12017500315A1 (en) 2017-07-10
CA2958800C (en) 2020-10-27
EP3639824A1 (en) 2020-04-22
IL250251A0 (en) 2017-03-30
CN106659717B (zh) 2019-09-06
CR20170069A (es) 2017-04-28
CL2017000391A1 (es) 2017-08-18
AR101674A1 (es) 2017-01-04
EP3182973B1 (en) 2019-09-18
US20200330462A1 (en) 2020-10-22
EA201790442A1 (ru) 2017-08-31
AU2015304847B2 (en) 2018-10-25
BR112017003705A2 (pt) 2017-12-05
JP2019189629A (ja) 2019-10-31
TW201618779A (zh) 2016-06-01
US20170304301A1 (en) 2017-10-26
EA031589B1 (ru) 2019-01-31
JP6546654B2 (ja) 2019-07-17
CN110403939A (zh) 2019-11-05
AU2015304847A1 (en) 2017-02-23
CN106659717A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
US11229646B2 (en) Method for treating gonorrhea with (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-C]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2A,5,8A-triazaacenaphthylene-3,8-dione
JP5389013B2 (ja) 抗菌剤としての三環式含窒素化合物
EP2041145B1 (en) Azatricyclic compounds and their use
JP2010521518A (ja) 化合物
JP2010524887A (ja) 抗菌剤としての含窒素三環式複素環化合物
US20100184751A1 (en) Heterocyclic compounds for the treatment of tuberculosis
US20110009394A1 (en) Tricyclic nitrogen compounds and their use as antibacterial agents
ES2351377T3 (es) Compuestos tricíclicos que contienen nitrógeno como agentes antibacterianos.
HK1138000B (en) Tricyclic nitrogen containing compounds as antibacterial agents

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/08/2015, OBSERVADAS AS CONDICOES LEGAIS

B25G Requested change of headquarter approved

Owner name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB)